Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Serge Halazy"'
Autor:
Serge Halazy
Publikováno v:
ARKIVOC, Vol 2006, Iss 7, Pp 496-508 (2006)
Externí odkaz:
https://doaj.org/article/dafee62c135f4883b243754f43599fed
Autor:
Serge Halazy
Publikováno v:
Molecules, Vol 8, Iss 4, Pp 349-358 (2003)
n/a
Externí odkaz:
https://doaj.org/article/dc782c19353c4a698fdf7dcec0ae1432
Autor:
Serge Halazy, Matthias K. Schwarz
Publikováno v:
CHIMIA, Vol 58, Iss 9 (2004)
Generally referred to as Europe's largest Biotech company, Serono, with global headquarters in Geneva, has long been known for its portfolio of therapeutic proteins, which has, so far, resulted in market approvals of several recombinant products in t
Externí odkaz:
https://doaj.org/article/f3c1d8efc62148939ce24a071c14f29c
Autor:
Jeffrey P. Shaw, Arthur Roach, Paola Zaratin, Claudio Giachetti, Anne-Cécile Trillat, Anna Quattropani, Tiziana Adage, Dominique Perrin, Oxana Guerassimenko, Ilya Chumakov, Laurent Cavarec, Serge Halazy, Beatrice Greco
Publikováno v:
European Neuropsychopharmacology. 18:200-214
Non-competitive N-methyl-d-aspartate (NMDA) blockers induce schizophrenic-like behavior in healthy volunteers and exacerbate symptomatology in schizophrenic patients. Hence, a compound able to enhance NMDA neurotransmission by increasing levels of d-
Autor:
‡ Anne-Marie De Raemy-Schenk, Dennis Church, Lucia Golzio, Rocco Cirillo, Russell J. Thomas, Anthony Nichols, Enrico Gillio Tos, Claudio Giachetti, David Covini, Claude Barberis, Pittet Pierre-Andre, Anna Quattropani, and André Chollet, Matthias Schwarz, Charles G. Bradshaw, Richard Coxhead, Guidon Ayala, Alexander Scheer, Marc Missotten, Serge Halazy, Jerome Dorbais, Paolo Marinelli, Véronique Colovray
Publikováno v:
Journal of Medicinal Chemistry. 48:7882-7905
We report a novel chemical class of potent oxytocin receptor antagonists showing a high degree of selectivity against the closely related vasopressin receptors (V1a, V1b, V2). An initial compound, 7, was shown to be active in an animal model of prete
Autor:
Steve Arkinstall, Pascale Gaillard, Denise Gretener, Cedric Szyndralewiez, Dennis Church, Christian Chabert, Vittoria Ardissone, Rocco Cirillo, Jean-Pierre Gotteland, Isabelle Jeanclaude-Etter, Montserrat Camps, Serge Halazy, Yves Cambet, Anthony Nichols, Pierre-Alain Vitte
Publikováno v:
Journal of Medicinal Chemistry. 48:4596-4607
Several lines of evidence support the hypothesis that c-Jun N-terminal kinase (JNKs) plays a critical role in a wide range of diseases including cell death (apoptosis)-related disorders (neurodegenerative diseases, brain, heart, and renal ischemia, e
Autor:
Jean-Pierre Gotteland, Thomas Rückle, Montserrat Camps, Tania Grippi-Vallotton, Xuliang Jiang, Christian Chabert, Dennis Church, Steve Arkinstall, Wolfgang H. B. Sauer, Isabelle Martinou, Marco A. Biamonte, Anthony Nichols, Serge Halazy, Yves Cambet
Publikováno v:
Journal of Medicinal Chemistry. 47:6921-6934
Several lines of evidence support the hypothesis that c-Jun N-terminal kinases (JNKs) play a critical role in a wide range of disease states including cell death (apoptosis)-related and inflammatory disorders (epilepsy, brain, heart and renal ischemi
Autor:
Serge Halazy
Publikováno v:
Pharmacogenomics. 5:757-761
The way to discover drugs is rapidly changing, not only because new technologies have emerged that have changed the landscape, but also because the time has come, due to both economical and ethical reasons, to move to the next generation of drugs. Th
Autor:
Patrick Gerber, Giulio Casi, Serge Halazy, Bruno Antonsson, Olivier Terradillos, Agnes Bombrun
Publikováno v:
Journal of Medicinal Chemistry. 46:4365-4368
There is compelling evidence that Bax channel activity stimulates cytochrome c release leading ultimately to cell death, which is a key event in ischemic injuries and neurodegenerative diseases. Here 3,6-dibromocarbazole piperazine derivatives of 2-p
Autor:
Serge Halazy
Publikováno v:
Expert Opinion on Therapeutic Patents. 9:431-446
G-protein coupled receptors (GPCR) represent a large family of receptors, which have been and still are targets of choice for drug discovery. Among the different tools offered to medicinal chemists to design potent and selective GPCR agonists or anta